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Acquired immunodeficiency syndrome (AIDS) cases are on the rise globally. To date, there is still no effective measure to
eradicate the causative agent, human immunodeficiency virus (HIV). Highly active antiretroviral therapy (HAART) is being used
in HIV/AIDS management, but it results in long-term medication and has major drawbacks such as multiple side effects, high
cost, and increasing the generation rate of escape mutants. In addition, HAART does not control HIV-related complications, and
hencemoremedications and furthermanagement are required.With this, other alternatives are urgently needed. In the past, small-
molecule inhibitors have shown potent antiviral effects, and some of them are now being evaluated in clinical trials. The challenges
in developing these small molecules for clinical use include the off-target effect, poor stability, and low bioavailability. On the other
hand, antibody-mediated therapy has emerged as an important therapeuticmodality for anti-HIV therapeutics development.Many
antiviral antibodies, namely, broad neutralizing antibodies (bnAbs) against multiple strains of HIV, have shown promising effects
in vitro and in animal studies; further studies are ongoing in clinical trials to evaluate their uses in clinical applications. This short
review aims to discuss the current development of therapeutic antibodies against HIV and the challenges in adopting them for
clinical use.
1. Current HIV Treatments
Thediscovery ofHAART in 1996 has successfully reduced the
global mortality rate due to HIV/AIDS [1]. This therapeutic
strategy targets multiple viral proteins that are essential for
viral replication and dissemination (e.g., envelope protein,
reverse transcriptase, integrase, and protease), instead of
targeting a single target. This combination therapy could
potently suppress the viral load to minimal level. However,
the treatment cost is extremely high and this therapy often
results in numerous side effects that significantly affect the
patients’ life quality [2]. Depending on the conditions, the
mild side effects could be weight loss, diarrhoea, anaemia,
constipation, dizziness, insomnia, headache, fatigue, rashes,
abdominal pain, emotions, nausea, and vomiting, while the
potentially fatal complications are liver failure, lipodystrophy,
and neurological and cardiovascular diseases [2]. In addition
to physical health, other problems in mental and social
health have also been reported [2]. It has also been shown
that the use of HAART leads to long-term medication of
HIV/AIDS patients, and it could introduce multiple drug-
resistant escape mutants due to the high mutation rate and
recombination frequency of the virus [3]. A large number of
drug-resistant HIV variants have been previously reported,
and they are known to be resistant to various drug groups
such as nucleoside reverse transcriptase inhibitors (NRTIs),
nonnucleoside reverse transcriptase inhibitors (NNRTIs),
protease inhibitors, integrase inhibitors, and entry inhibitors
[3]. Hence, other more effective and less toxic alternatives are
urgently needed to treatHIV/AIDS.A proper use of anti-HIV
drug is also important in order to control the overwhelming
number of escape mutants.
In the past, small-molecule inhibitors have demon-
strated promising antiviral effects against HIV [4–7]. These
inhibitors target various viral proteins such as integrase [8],
nucleocapsid [9], capsid [10], and envelope [11] as well as
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cellular proteins of target cells such as CD4 [12], kinases
[13], and cellular cofactor [14]. T20 peptide (Enfuvirtide)
is the first HIV entry inhibitor approved by United States
Food and Drug Administration (U. S. FDA) in 2003 [15]
followed by the approval of the first chemokine receptor 5
(CCR5) small-molecule antagonist, Maraviroc (Selzentry) in
2007 [16]. However, these drugs have their limitations in the
clinical applications [6, 17].Meanwhile, other small-molecule
inhibitors are being evaluated in clinical trials. For instances,
small-molecule NNRTIs, cabotegravir, and rilpivirine were
evaluated in randomised phase 2b trials and the result of the
trial has been recently published [18]. Following Maraviroc,
small-molecule CCR5 antagonists, aplaviroc, and vicriviroc
are currently being evaluated in phase 2b clinical trials for
HIV therapy [19]. A small-molecule ABX464 that inhibits
HIV replication is also expected to enter phase 2b trials
in 2018 [20]. Despite the advancement of biological and
chemical engineering technology, it remains a huge challenge
to deliver a safe, stable, and functional molecule into the host
system to completely eradicate the residing virus [6].
Antibody-based therapies possess several advantages
over the chemical-based treatment in various aspects such
as specificity and safety [21]. A number of therapeutic
antibodies have been approved by FDA for cancer therapies
[22]. In the past three years, therapeutic antibodies targeting
programmed death protein 1 (PD-1) and programmed death
ligand 1 (PDL1) to boost human immune responses against
cancer cells [23] have been approved by FDA to treat various
cancers including melanoma [24], non-small cell lung cancer
(NSCLC) [25], and head and neck squamous cell carcinoma
(HNSCC) [26]. For viral infection prevention and treatment,
several antibodies targeting multiple types of viruses such
as human cytomegalovirus (HCMV), influenza, respiratory
syncytial virus (RSV), Ebola, rabies, and HIV are being eval-
uated in clinical trials [21]. The development of therapeutic
antibodies, in particular, the broad neutralizing antibodies
(bnAbs) against various HIV strains, will be emphasized and
discussed in later sections.
2. Development of HIV-1-Neutralizing
Antibodies against HIV/AIDS
Broad neutralizing antibodies (bnAbs) are neutralizing anti-
bodies that neutralize multiple HIV-1 viral strains by tar-
geting conserved epitopes of virus [60]. BnAbs have shown
promising effects against various HIV strains and have
significantly contributed to HIV vaccine development [60].
The earliest bnAb, b12 were discovered in 1991 [61], and
increasing bnAbs have been seen in recent years [60]. All
of the bnAbs information is freely available on a website
known as broadly neutralizing antibodies electronic resource
(bNAber) which aims to support the researchers to generate
a potent HIV vaccine [62]. Table 1 shows a list of bnAbs
targeting multiple HIV-1 epitopes in the past 10 years. These
bnAbs were raised from blood of HIV-1 infected patients and
this information is tabulated in Table 1. Generally, anti-HIV
bnAbs can be categorized into two groups: first and second
[63]. Both of these groups differ from the method used for
generation of bnAbs and their functionalities. Examples of
“first-generation” antibodies are b12, 2G12, 4E10, and 2F5.
These bnAbs were developed from Epstein-Barr virus- (EBV-
) immortalized B cells and generated using phage-display
methods [63]. Although these bnAbs resulted in 50%–88%
of neutralization breadth, they are not ideal for antibody-
based vaccine mainly due to the relatively low neutralization
efficacy and limitation of method such as antibody specificity
selection and lack of high throughput screening option
[64]. On the other hand, “second-generation” bnAbs possess
improved neutralization potency and offer high flexibility in
technology manipulation. The advancement of technology
allows the selection of chronically HIV-1-infected “Elite
neutralizers,” new screening and selection method, and new
antibody isolation and analysis method [64]. Examples of
“second-generation” bnAbs are PG9, PG16, CH01, PGT145,
PGT121, PGDM1400, 10-1074, 10E8, VRC01, 3BNC117, and
CH103.
To date, none of the FDA-approved therapeutic anti-
bodies are used for HIV treatment. The development of
therapeutic antibodies against HIV is ongoing and many of
them have successfully progressed to human clinical trials
[46, 65]. Table 2 shows the anti-HIV antibodies that are being
evaluated in different phases of trials. HIV-1 envelope protein
is a popular therapeutic target for various antiviral pharma-
ceuticals and vaccine design [66]. Scheid and group demon-
strated the result of phase 2a trial using HIV Env-specific
antibody, 3BNC117 on 13 HIV-infected patients.They showed
that the broad neutralizing antibody (bnAb) 3BNC117 exerted
strong selective pressure on HIV-1 emerging from latent
reservoirs [43]. Similarly, another monoclonal antibody, 10-
1074 targeting V3 glycan site of HIV-1 Env protein, showed
potent effect and high tolerant limit in phase I trial [44]. Bar
and colleagues showed another bnAb, VRC01 to effectively
suppress the plasma viremia below detectable concentration
in phase I trial [45]. The same study also highlighted the
emergence of VRC01-resistant HIV after the exposure as the
main challenge [45]. Other monoclonal antibodies targeting
HIV envelope glycoproteins that are currently under phase I
trials are PGDM1400, PGT121, N6, and 10E8v4 (Table 2)
[46]. Recently, Xu and group generated highly potent trispe-
cific antibodies by combining the specificity of PGDM1400,
VRC01, and 10E8v4 [47]. These engineered antibodies inter-
act with three different sites of envelope protein: membrane-
proximal external region (MPER)-, CD4-, and V1V2-binding
sites. These antibodies conferred a complete immunity by
displaying high breadth and potency against simian-human
immunodeficiency viruses (SHIVs) in nonhuman primates
compared to each parental antibody.This antibody developed
by Sanofi is expected to enter phase I trial in late 2018 [47].
Antibodies that are targeting cellular proteins essential
for HIV replication such as CD4 and coreceptors have
also been shown to efficaciously eradicate the HIV. Some
of these antibodies are undergoing clinical trials. TMB-355
(previously known as TMB-301), also known as ibalizumab,
targetsCD4 receptor andprevents the viruses frombinding to
them. A phase 3 trial demonstrated that ibalizumab is a safe
and well-tolerated drug and can be used as a monotherapy
especially for multidrug-resistant HIV patients with limited
treatment options [51]. Researchers are currently developing
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Table 1: Anti-HIV broad neutralizing antibodies (bnAbs) in the past 10 years.
Viral epitope Name Year Sample source References
V1V2 glycan site
PG9, PG16 2009 Clade A-infected African [27]
CH01 2011 Chronically infected donor (CH0219) [28]
PGT145 2011 Chronically infected donor 84 [29]
PGDM1400 2014 Chronically infected donor 84 [30]
V3 glycan site PGT121, PGT125, PGT135 2011 HIV-1 infected donor (at least 3 years) [29]
10-1074 2011 Clade A-infected African donor (patient 10) [31]
gp41 MPER
2F5 2009 PBMCs from patient SC44 [32]
4E10 2009 PBMCs from patient SC44 [32]
HK20 2010 Patients plasma that showed >80% neutralization [33]
M66.6 2011 PBMCs from patient SC44 [32]
CAP206-CH12 2011 Subtype C HIV-1-infected South African donor CAP206 [34]
10E8 2012 HIV-1-infected patient N152 [35]
m43 2012 Phage-display [36]
CD4 binding site
VRC01 2010 PBMCs from donor 45 [37]
HJ16 2010 Patients plasma that showed >80% neutralization [33]
HGN194 2010 Patients plasma that showed >80% neutralization [33]
3BNC117 2011 RU01 B-cell clones from patient donor [38]
3BNC55 2011 RU01 B-cell clones from patient donor [38]
VRC-PG04 2011 Clade A1/D infected donor [39]
VRC-CH31 2011 Chronically infected donor (CH0219) [28]
NIH45 2011 RU12 B-cell clones from patient donor [38]
8ANC195 2011 RU12 B-cell clones from patient donor [38]
8ANC131 2011 HIV-1 infected donor RU8 [38]
12A12 2011 RU16 B-cell clones from patient donor [38]
1B2530 2011 HIV-1 infected donor RU1 [38]
3BC176 2012 HIV-1 infected patient 3B [40]
3BC315 2012 HIV-1 infected patient 3B [40]
CH103 2013 HIV-1 infected donor CH505 [41]
N6 2016 HIV-1-infected patient Z258 [42]
Table 2: Therapeutic antibodies that are being evaluated in the clinical trials.
Source Target Name Clinical trial References
Viral
Env CD4 binding site 3BNC117 Phase 2a [43]
Env V3 glycan site 10-1074 Phase I [44]
Env CD4 binding site VRC01 Phase I [45]
V1V2 PGDM1400 Phase I [42]
Env V3 glycan site PGT121 Phase I [46]
Env MPER 10E8v4 Phase I [47]
Env CD4 binding site N6 Phase II [42]
Cellular
CCR5 HGS004 Phase I [48]
CCR5 PRO140 Phase III [49]
CCR5/CCR2 Cenicriviroc Phase III [50]
CD4 TMB-355 Phase III [51]
PDL1 BMS-936559 Phase I [52]
a new formulation of ibalizumab for the intramuscular
injection use [51]. Various antibodies targeting chemokine
coreceptor 5 (CCR5), such as HGS004, PRO140, and Ceni-
criviroc (Table 2), have shown promising antiviral effects
and are now being evaluated in clinical trials. An anti-
PDL1 antibody, BMS-936559 has been evaluated in a phase
I trial on HIV patients, and the results showed that the
immunologic checkpoint inhibitor could enhance the HIV-
specific immunity in a subset of participants in the trial
[52]. Apart from the abovementioned antibodies, other anti-
HIV therapeutic antibodies are being evaluated and these
antibodies have been discussed in several reviews [59, 67–69].
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Table 3: Challenges of FDA-approved anti-HIV therapeutic antibodies development.
Challenge Notes References
Method Phage-display library is the most commonly used technique for therapeutic antibody generation. [53]
The technique allows both genetic and chemical modification of antibody fragments. [54]
Cost The production cost of antibody is higher than the synthesis of small-molecule antivirals. Thegeneration of recombinant antibodies results in higher manufacturing cost. [21]
Host immunology Individuals’ immune responses towards therapeutic antibodies may be different [55]
Epidemiology Geographical distribution affects the resistance mechanism and neutralization escape of viralstrains [56]
Delivery Conjugation with cell-penetrating peptides improves the cellular delivery of antibodies. Smallerantibody formats such as Fabs, sdAbs, and scFvs also facilitate tissue delivery [57]
Stability Fc region engineering improves the half-life, stability, and the effector function of the antibody [58]
Resistant mutants Development of antibody-resistant HIV mutants has been reported in VRC01-treated patients,combination therapy will minimize the occurrence of virus mutation [45]
Toxicity IL-2 and IFN-𝛾 therapy that may be used as adjuvant therapy for bnAbs therapy to stimulateT-cell killing and HIV-1 transcription resulted in high level of cytotoxicity [59]
These investigational therapeutic antibodies are being evalu-
ated preclinically before entering the human trials.
Compared with other chemical-based or small-molecule
treatment, antibody-based treatment offers a more com-
prehensive targeting and neutralization, and hence a more
potent anti-HIV actions. One of the key components of
bnAbs is the IgG Fc region. Using humanized mouse mod-
els, Halper-Stromberg et al. demonstrated that the HIV
suppression by the passively transferred antibodies was
dependent on interaction of the IgG Fc with Fc receptors
of immune cells [70]. Other studies have also highlighted
the Fc receptor-mediated effector functions of bnAbs in
HIV inhibition through antibody-dependent cell-mediated
cytotoxicity (ADCC) against both free virus and virus-
infected cells [71, 72]. Fc domains of antibodies also interacted
with natural killer cells and phagocytes for viral particle
clearance and killing of virus-infected cells [73]. It is clear
that while reactivity and affinity of bnAbs play pivotal roles
in determining the antibody neutralization capacity, the Fc-
mediated effector mechanisms also play part in the antiviral
activities.
3. Challenges in Antibody-Based Therapies
As discussed above, antiviral antibodies serve as a highly
potential therapeutic modality against HIV. However, there
are multiple challenges in the development of these antibod-
ies. These challenges have intensively slowed down the FDA
approval of the anti-HIV antibodies into the market. This
section discusses the challenges in developing the antibodies
into clinical use (summarized in Table 3).
The main challenge of antibody therapy against HIV
is the method used for humanized antibody production.
Phage-displayed library is the most popular platform used to
generate therapeutic human antibodies in the past decade and
many of these phage-display-generated antibodies have been
approved by FDAor EuropeanMedicines Agency (EMA) [53,
74]. This technique enables the construction of antibodies in
Fab or scFv fragments and display on filamentous phage.The
antibodies are then isolated and enriched by panning against
antigen of interest. Due to the relatively lower throughput,
phage-display technique has been switched to cell sorting and
RT-PCR for antibody isolation. Use of these methods has
generated many more bnAbs known as “second-generation”
bnAbs. Various sources have been used for the therapeutic
antibody production against viruses, including total B cells
[75], singlememory B cells [21], and single plasmaB cells [21].
Several reports have also shown the efficacy of isolating the
antibodies from native phage libraries which possess potent
neutralization activities against viruses [76]. The downside
of this technique is that it cannot be used to identify new
neutralizing epitopes of virus [21]. This method has also
been described as a time-consuming and laborious approach
[77]. Other alternatives to generate the therapeutic antibodies
include proteomics-directed cloning of antibodies [78] and
deep sequencing of paired antibodies encoding genes [79].
The development of antibody generation technique is also
highly associated with the production cost.The advancement
of technologies allows the production of recombinant anti-
bodies with improved therapeutic effects as well as other
refined properties including tissue delivery and stability.
For instance, antibody in single-domain antibodies (sdAbs)
format allows an efficient target binding and rapid tissue pen-
etration compared to the conventional full-length antibodies;
this may enhance the antiviral activities [80]. However, this
strategy needs to be reconsidered as cumulative evidences
have shown the importance of Fc region of Abs in antiviral
action; antibodies without Fc region would significantly
reduce the overall neutralizing activities [70–72]. To improve
the stability and biodistribution of therapeutic full-length
antibodies and the effector functions, Fc region engineering
plays an important role in improving the antibody clinical
efficacy [81, 82]. Antibody-based therapies are generally well-
tolerated and safe; however, this can be further improved
by antibody engineering as previously described [83]. While
antibody engineering is speculated to benefit the future of
HIV/AIDS therapy, thesemodifications will increase the pro-
duction cost compared to the standardized manufacturing
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protocol as well as the synthesis of antiviral small molecules.
The production cost is the key factor for anti-HIV antibody
therapy due to the smaller market in viral diseases compared
to cancer diseases [21].There is also a rising concern following
the increasing number of FDA-approved small-molecule
inhibitors for HIV/AIDS therapy [10, 13, 18, 20]. Although
the antibody- and molecule-based therapeutics have differ-
ent antiviral mechanisms, the comparison and competition
between the antiviral antibodies and the substantial number
of small-molecule inhibitors in the market is unavoidable.
Another challenge of developing therapeutic antibodies is
the biological variation from host to host. Certain population
of HIV-infected patients may not respond to a particular
antibody or is suitable even though it has been proven effica-
cious and safe in a group of patients who have differences in
terms of individuals’ immunology, vaccination, diet, lifestyle,
and geographical factors [21]. The treatment failure is also
highly related to the biology of target virus including the
mechanism of infection, mutation rate, and neutralization
escape [84].Other key challenges are the delivery and stability
of antibodies for HIV therapies (Table 2). As tabulated
in Table 1, all of the drug targets are viral and cellular
proteins or receptors. Recent reports have highlighted the
potential of targeting intracellular proteins using therapeutic
antibodies for the development of HIV/AIDS therapies [85,
86]. However, conventional antibodies do not penetrate into
the cells and target intracellular proteins [87]. To solve
this problem, conventional antibodies can be conjugated
with cell penetrating peptides (CPPs) derived from various
sources to enter the cell cytoplasm [88]. Antibodies in smaller
format such as Fabs, scFvs, and sdAbs (with Fc removal)
have also been constructed for this purpose [57, 89, 90].
These antibodies have targeted various intracellular proteins
including capsid [91], integrase [92], and other accessory
proteins such as Nef [93], Vif [94], Tat [95], and Rev [96].The
clinical application of these intracellular-targeting antibodies
remains to be seen.
Compared to other therapeutic modalities such as
HAART and other small-molecule inhibitors, antiviral bnAbs
are active against multiple types of HIV strains at low
doses with acceptable toxicities [97]. For example, 3BNC117
could prevent mucosal transmission in high-dose challenge
in humanized mouse models at low doses [98]. On the
other hand, combination of NIH45-46m2, 10-1074, and
10E8 resulted in 100% neutralization of HIV-1 variants at a
low concentration (IC
50
of ≤0.37 𝜇g/mL) compared to the
individual bnAb alone [99]. Although the toxicity of anti-
HIV bnAbs therapy is less reported, it has been reported in
other adjuvant therapies that may be used to complement the
antibody therapy such as IL-2 and IFN-𝛾 cytokine therapy
[59].
Last but not least, the rapid viral resistance developed
from the bnAbs treatment is striking and has drawn con-
siderable attention. This is mainly due to the high mutation
rate of HIV-1. The resistance has been reported in various
bnAbs targeting multiple sites including V1/V2, V3, and
CD4 binding site. Bouvin-Phey et al. reported that HIV-1
clade B has increased resistance towards the bnAbs targeting
gp120 as shown by VRC01, NIH45-46, PG9, PG16, PGT121,
and PGT128 [99]. Interestingly, the same study has also
shown that no increase of viral resistance was seen in bnAbs
targeting MPER of gp41 such as 2F5 and 4E10 [99]. This
could be due to the lack of selective pressure and/or a
weak tolerance to mutations in this particular region [99].
Similarly, the viral resistance of bnAbs has also been predicted
using several computational and mathematical models [100,
101]. To circumvent this issue, multispecific bnAbs and
combination of bnAbs have been developed to concurrently
target various epitopes of a protein to reduce the chances of
viral resistance. This includes the recent development of a
trispecific bnAbs targeting two CD4-binding sites andMPER
[102], and a combination of two to four bnAbs targeting CD4-
binding site, V1V2, V3, and MPER [103].
4. Future Perspectives and Conclusions
The abovementioned challenges must be looked into before
the therapeutic antibodies are deemed suitable for clinical
use. Development of technology and bioengineering such as
advancement of antibody generation and isolation methods,
improvement of target delivery, and specificity play important
roles in improving the antiviral activities of therapeutic
antibodies. Based on current literature, many studies demon-
strated that antibody-mediated antiviral treatments have
yet achieved complete inhibition against HIV-1. This may
suggest that treatment using therapeutic antibodies may not
be suitable to be used as a “standalone” therapy although
extensive efforts are ongoing. This therapeutic modality may
pose a higher value when used in combination with current
anti-HIV therapies such as HAART or other antiviral small-
molecule inhibitors. For example, it has been shown that
the bnAb 3BNC117 when used in combination with HAART
could enhance the host immune response against HIV-1 and
leads to significant delay of viral rebound after treatment
cessation [63, 104]. Although the combination treatment of
small-molecule inhibitors and antiviral antibodies has not
been studied, it is speculated that it will drastically improve
the neutralizing potency of the HIV-1. This speculation,
however, requires further investigations for validation. In
addition to maximizing the neutralization efficacy, combi-
nation treatment targeting multiple sites of protein is also
anticipated to significantly avert the selection of escape
variants [97].
The discovery of bnAbs has also posed a significant
impact on the development of anti-HIV vaccine. While
bnAbs are able to tackle the extremely high diversity of HIV-
1, it is understood that having a safe vaccine eliciting bnAbs
could be an effective measure to control HIV spreading.
However, there are no vaccination strategies by far to elicit
the effective bnAbs responses [105]. Several attempts have
been made to develop the vaccination strategy mainly using
animal models. In both macaque and rabbit models, sequen-
tial vaccination with gp120 and gp140 proteins has shown
improved potency of neutralization, respectively [106, 107].
Similarly, sequential vaccination with three gp120 variants
also demonstrated potent neutralization [108]. To date, it
remains unknown to elicit the bnAbs from the HIV patients
through vaccination. The main challenges are the HIV-1
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diversity and later on rapid viral resistance. Sequential vac-
cination with various immunogens with conserved regions
may promote the B cell maturation and antibody responses.
Therapeutic antibodies are known as “magic bullets” due
to the fact that they can treat various diseases and infec-
tions. A number of FDA-approved therapeutic antibodies
in the current market highlight the potential of adopting
antibodies for disease control. Broad neutralizing antibodies
have demonstrated potent antiviral action against various
strains of HIV-1 and a large number of them are currently
being evaluated in the clinical trials. Continuous efforts are
in progress to elucidate their potential use for anti-HIV treat-
ment in clinics. Overcoming the abovementioned challenges
will undoubtedly improve the application of therapeutic
antibody to HIV/AIDS management in the future.
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